Results 101 to 110 of about 33,193 (249)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

On the G-protein-coupled receptor heteromers and their allosteric receptor-receptor interactions in the central nervous system: focus on their role in pain modulation [PDF]

, 2013
The modulatory role of allosteric receptor-receptor interactions in the pain pathways of the Central Nervous System and the peripheral nociceptors has become of increasing interest.
Agnati, Luigi F, Borroto-Escuela, Dasiel O, Fuxe, Kjell, Rivera, Alicia, Romero-Fernandez, Wilber, Tarakanov, Alexander O, Van Craenenbroeck, Kathleen   +6 more
core   +3 more sources

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain

Scientific Reports, 2018
Altered pain sensations such as hyperalgesia and allodynia are characteristic features of various pain states, and remain difficult to treat. We have shown previously that spinal application of dipeptidyl peptidase 4 (DPP4) inhibitors induces strong ...
Kornél Király, Márk Kozsurek, Erika Lukácsi, Benjamin Barta, Alán Alpár, Tamás Balázsa, Csaba Fekete, Judit Szabon, Zsuzsanna Helyes, Kata Bölcskei, Valéria Tékus, Zsuzsanna E. Tóth, Károly Pap, Gábor Gerber, Zita Puskár   +14 more
doaj   +1 more source

The neural mechanisms of mindfulness-based pain relief: a functional magnetic resonance imaging-based review and primer. [PDF]

, 2019
The advent of neuroimaging methodologies, such as functional magnetic resonance imaging (fMRI), has significantly advanced our understanding of the neurophysiological processes supporting a wide spectrum of mind-body approaches to treat pain. A promising
Aguirre, Amanzio, Andrews-Hanna, Atlas, Atlas, Basbaum, Behzadi, Beitz, Benedetti, Bingel, Birn, Brown, Buchel, Buhle, Bushnell, Carlson, Casey, Cherkin, Coghill, Coghill, Creswell, Creswell, Creswell, Crick, Critchley, Daubenmier, Davey, Davis, Day, Deyo, Dunne, Dzau, Eippert, Eippert, Farb, Fox, Fox, Frid, Gard, Garland, Garland, Gatchel, Gaylord, Grant, Grant, Grevert, Grossman, Halassa, Han, Harris, Harrison, Holzel, Hughes, Jain, Kabat-Zinn, Kabat-Zinn, Kabat-Zinn, Kety, King, Kingston, Kong, Koyama, Kucyi, Lazar, Levine, Lindsay, Lord, Lui, Lutz, Lutz, Lutz, MacCoon, MacCoon, Maki-Marttunen, Mantyh, Mantyh, May, McAlonan, McCracken, Morone, Morone, Nelson, O'Doherty, Oshiro, Perthen, Peters, Petrovic, Petter, Poerio, Rahl, Restom, Rolls, Rosenkranz, Rostrup, Salomons, Saloner, Schooler, Schutze, Seminowicz, Seminowicz, Shapiro, Sharon, Sharon, Shires, Spreng, Sprenger, Starr, Stephenson, Steward, Svedin, Tang, Taylor, Taylor, Teper, Tracey, Turner, Vago, Valet, Villemure, Wager, Wager, Wager, Wang, Watkins, Way, Weese, Wells, Xu, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zeidan, Zikopoulos, Zikopoulos, Zikopoulos, Zubieta   +142 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

The Central Reinforcing Properties of Ethanol Are Mediated by Endogenous Opioid Systems: Effects of Mu and Kappa Opioid Antagonists.

Revista Argentina de Ciencias del Comportamiento, 2009
Endogenous opioid systems are implicated in the reinforcing effects of ethanol and may play a substantial role in modulating the central reinforcing effects of ethanol early in ontogeny.
Norman E. Spear, Elena I. Varlinskaya, Michael E Nizhnikov   +2 more
doaj  

Molecular docking study of Papaver alkaloids to some alkaloid receptors [PDF]

Research Journal of Pharmacognosy, 2017
Background and objectives: More than 40 different alkaloids have been obtained from opium the most important of which are morphine, codeine, papaverine, noscapine and tabaine.
A. Nofallah, Sh. Hooshmand*, M. Gholami, M. Piri   +3 more
doaj  

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. [PDF]

, 2015
RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice.
C Giuliano, C Giuliano, David N. Stephens, David R. Wille, DM Ignar, DN Stephens, DW Oslin, EA Rabiner, Edward T. Bullmore, EE Codd, F Kiefer, GH Jones, H Wit de, H Ziauddeen, HM Pettinati, JR Volpicelli, JS Rhodes, Kay Maltby, LA Berner, LA Parker, LD Middaugh, LS Hwa, Manolo Mugnaini, NK Kamdar, P Monti, PJ Nathan, PJ Nathan, Pradeep Nathan, S Loeber, Sam R. Miller, Sandra Sanchez-Roige, Tamzin L. Ripley, TJ Phillips, TL Ripley   +33 more
core   +1 more source

Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels

Molecular Brain Research, 1995
Chronic administration of opioid antagonists has been shown to increase radioligand binding to brain opioid receptors. The present study was conducted to determine whether chronic exposure to the opioid antagonist naltrexone would similarly increase mu opioid receptor gene expression as measured by mRNA levels.
E M, Unterwald, J M, Rubenfeld, Y, Imai, J B, Wang, G R, Uhl, M J, Kreek   +5 more
openaire   +2 more sources